Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Guide RNA reprogramming facilitates minimized tracrRNA-dependent off-target and versatile CRISPR/Cas9 engineering.

Nature communications·2026

Same author

HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering.

Journal for immunotherapy of cancer·2026

Same author

Structural insight into IscB's RNA-lid-based inactivation mechanism.

Nature structural & molecular biology·2026

Same author

Mining antibody functionality via AI-guided structural landscape profiling.

Nature communications·2026

Same author

Chimeras co-targeting antigens and FcγRIIb trigger degradation of extracellular soluble proteins and pathological aggregates.

Nature communications·2025

Same author

An overview of vital functions of human ecdysoneless (ECD), a highly conserved protein.

Bioscience reports·2025

Search research articles

Related Experiment Video

Updated: Nov 2, 2025

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics.

Yuan Wang¹, Ruina Jin¹, Bingqing Shen²

¹State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin, China.

Science Advances

|June 12, 2021

Summary

A new microfluidic platform enables high-throughput functional screening of antibodies for cancer immunotherapy. This technology accelerates the discovery of potent bispecific T cell engager (BiTE) antibodies and costimulatory receptor agonists.

More Related Videos

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

Related Experiment Videos

Last Updated: Nov 2, 2025

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

Area of Science:

Biotechnology
Immunology
Microfluidics

Background:

High-throughput antibody isolation methods often lack functional readouts beyond simple binding.
This limitation hinders the development of advanced cancer immunotherapeutics like bispecific T cell engagers (BiTEs) and costimulatory receptor agonists.

Purpose of the Study:

To develop a microfluidic platform for high-throughput functional screening of antibodies.
To enable the isolation of antibodies with desired functionalities for cancer immunotherapy.

Main Methods:

A droplet-based microfluidic platform was combined with a lentivirus transduction system.
Millions of antibodies were functionally screened to identify hits with specific therapeutic functions.

Main Results:

Functional CD40 agonistic antibodies, present at a low frequency (<0.02%), were identified in two screening rounds.
The platform successfully identified active anti-Her2 × anti-CD3 BiTE antibodies from a diverse library.

Conclusions:

The developed platform significantly enhances the discovery of functional antibodies for next-generation cancer immunotherapies.
This technology has the potential to revolutionize cancer drug development and advance medical research.